Vator Securities advises Moberg Pharma on 121 MSEK Rights Issue

Comment on transaction

"The financing we have secured gives us the opportunity to fully exploit MOB-015's potential, both through the registration activities and launch preparations in Europe and an additional clinical study for the US market. The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect," says Anna Ljung, CEO of Moberg Pharma.

Press release

About Moberg Pharma

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company's goal is to receive its first market approval and launch MOB-015 in 2023.

The Case

Moberg Pharma’s lead asset, MOB-015, has demonstrated world-leading ability to kill nail fungus in two Phase 3 studies.

Targeting category leadership with USD 250-500 million in annual product sales potential. Partnerships with potential milestones of USD 120 million + royalties are already in place: Bayer (EU), Taisho Pharmaceuticals (Japan), DongKoo Bio & Pharma (Republic of Korea), Allderma (Scandinavia) and Cipher Pharmaceuticals (Canada).

Proven commercial track record with leading OTC brand KerasalNail® for nail fungus, building a SEK 440 million franchise with 30% market share in the US, divested for SEK 1.4 billion in 2019 – commercialization process to be repeated for MOB-015.

Market approval and launch of MOB-015 expected in 2023, while preparations are fully underway for a new North American Phase 3 study to enable US approval and strengthen claims globally.

Moberg Pharma's website